The estimated Net Worth of Christopher Mirabelli is at least $827 millier dollars as of 26 January 2024. Christopher Mirabelli owns over 5,000 units of Leap Therapeutics Inc stock worth over $14,088 and over the last 19 years he sold LPTX stock worth over $0. In addition, he makes $813,172 as Chairman of the Board at Leap Therapeutics Inc.
Sign up
Christopher Mirabelli LPTX stock SEC Form 4 insiders trading
Christopher has made over 4 trades of the Leap Therapeutics Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of LPTX stock worth $13,850 on 26 January 2024.
The largest trade he's ever made was buying 1,094,891 units of Leap Therapeutics Inc stock on 20 June 2005 worth over $6,000,003. On average, Christopher trades about 136,454 units every 340 days since 2005. As of 26 January 2024 he still owns at least 5,086 units of Leap Therapeutics Inc stock.
You can see the complete history of Christopher Mirabelli stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Mirabelli biography
Dr. Christopher K. Mirabelli Ph.D. serves as Chairman of the Board of the Company. He has served as the Chairman of our Board since January 2016 and as a director since January 2011. Dr. Mirabelli formerly served as our Chief Executive Officer and President from our inception in January 2011 until April 2020. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since August 2000. From December 1999 to May 2000, Dr. Mirabelli served as president of pharmaceutical research and development and as a member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Boston Biomedical Innovation Center, the Dana Farber Cancer Institute Business Development Council and the Longview Ventures Investment Committee. Dr. Mirabelli is a member of the Board of Trustees of Guilford College, Board of Directors of the Fredonia College Foundation and Board of Overseer's of the Scripts Research Institute. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.
What is the salary of Christopher Mirabelli?
As the Chairman of the Board of Leap Therapeutics Inc, the total compensation of Christopher Mirabelli at Leap Therapeutics Inc is $813,172. There are 2 executives at Leap Therapeutics Inc getting paid more, with Douglas Onsi having the highest compensation of $816,959.
How old is Christopher Mirabelli?
Christopher Mirabelli is 65, he's been the Chairman of the Board of Leap Therapeutics Inc since 2020. There are 2 older and 8 younger executives at Leap Therapeutics Inc. The oldest executive at Leap Therapeutics Inc is James Cavanaugh, 82, who is the Independent Director.
What's Christopher Mirabelli's mailing address?
Christopher's mailing address filed with the SEC is C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE, MA, 02141.
Insiders trading at Leap Therapeutics Inc
Over the last 8 years, insiders at Leap Therapeutics Inc have traded over $0 worth of Leap Therapeutics Inc stock and bought 10,810,588 units worth $40,517,079 . The most active insiders traders include Advisors Llcperceptive Life..., Christopher Mirabelli et Ltd. Bei Gene,. On average, Leap Therapeutics Inc executives and independent directors trade stock every 142 days with the average trade being worth of $1,990,710. The most recent stock trade was executed by Christopher Mirabelli on 26 January 2024, trading 5,000 units of LPTX stock currently worth $13,850.
What does Leap Therapeutics Inc do?
leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.
What does Leap Therapeutics Inc's logo look like?
Complete history of Christopher Mirabelli stock trades at Leap Therapeutics Inc, Proteostasis Therapeutics Inc et Cortexyme Inc
Leap Therapeutics Inc executives and stock owners
Leap Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Douglas Onsi,
President, Chief Executive Officer, Director -
Augustine Lawlor,
Chief Operating Officer -
Christopher Mirabelli,
Chairman of the Board -
Cynthia Sirard,
Chief Medical Officer -
Mark O'Mahony,
Chief Manufacturing Officer -
Nissim Mashiach,
Independent Director -
Joseph Loscalzo,
Independent Director -
William Li,
Independent Director -
Thomas Dietz,
Lead Independent Director -
James Cavanaugh,
Independent Director -
Monica Bertagnolli,
Independent Director -
John W Littlechild,
Director -
Ventures Ix, L.P.Healthcare...,
-
Harold R Werner,
10% owner -
Lilly & Co Eli,
10% owner -
Patricia A. Martin,
Director -
Christian M Richard,
Director -
Richard Schilsky,
Director -
Advisors Llcperceptive Life...,
-
Ventures Viii, L.P.Health C...,
-
Jason Baum,
Chief Scientific Officer -
Christine Granfield,
VP, Head of Reg Affairs/Qual -
Ltd. Bei Gene,,
10% owner